康泰医学(300869) - 2025 Q4 - 年度业绩预告
2026-02-04 09:22
Financial Performance Forecast - The company expects a net profit loss for 2025, estimated between CNY 17 million and CNY 33 million, compared to a loss of CNY 77.9 million in the previous year[8] - The net profit after deducting non-recurring gains and losses is projected to be a loss between CNY 30 million and CNY 59 million, compared to a loss of CNY 95.08 million in the previous year[8] - The anticipated decrease in inventory impairment provision for 2025 is expected to reduce the net profit loss compared to the previous year[9] - The financial forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an accounting firm[8] - The company has communicated with the accounting firm regarding the performance forecast, and there are no discrepancies between both parties[8] Investor Advisory - Investors are advised to pay attention to the significant loss expected in 2025 and the potential impact of product market demand changes on the company's performance[10] - The report serves as a temporary trustee management report regarding the company's bond issuance and does not constitute investment advice[5] - The company emphasizes the importance of independent judgment by investors regarding the reported matters[12] Bondholder Interests - The company will continue to monitor the repayment of principal and interest on the bonds and other matters significantly affecting bondholders' interests[11]
环旭电子(601231) - 2025 Q4 - 年度业绩
2026-02-04 07:50
证券代码:601231 证券简称:环旭电子 公告编号:2026-014 环旭电子股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审计, 具体数据以公司2025年度报告中披露的数据为准,提请投资者注意投资风险。 一、2025年主要财务数据和营业收入构成 1、主要财务数据 单位:人民币元 | 项 目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 59,195,055,821.58 | 60,690,651,098.10 | -2.46 | | 营业利润 | 2,104,570,655.60 | 1,872,481,650.87 | 12.39 | | 利润总额 | 2,139,493,055.52 | 1,853,816,573.41 | 15.41 | | 归属于上市公司股东的净利润 | 1,853,439,277.28 | 1,652,48 ...
重庆啤酒(600132) - 2025 Q4 - 年度业绩
2026-02-04 07:50
本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审计, 具体数据以公司2025年年度报告中披露的数据为准,提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位:人民币万元 证券代码:600132 证券简称:重庆啤酒 公告编号:2026-004 重庆啤酒股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 (三)经营业绩变动情况说明 2025年,公司在"嘉速扬帆"战略指引下,积极应对外部环境变化,通过持 续推进优化产品结构,加速新品布局,积极拓展非现饮渠道,不断深耕"大城市" 计划等重点业务举措,展现出良好的经营韧性。2025年,公司销量实现同比增长 0.68%,优于行业表现,营业总收入同步保持稳健增长。同时,受益于大宗原材 料成本的下降和供应网络优化项目带来了成本节约,毛利率有所提升。此外,为 巩固和拓展市场份额,公司加大市场投入力度,广告及市场营销费用较2024年增 长。 | 项目 | 本报告期 | 上年同期 | 增减变动 幅度(%) | | --- | -- ...
巴比食品(605338) - 2025 Q4 - 年度业绩
2026-02-03 09:50
Financial Performance - The company achieved total operating revenue of RMB 185,905.00 million, representing a year-on-year increase of 11.22%[5] - Net profit attributable to shareholders was RMB 27,299.89 million, a decrease of 1.30% compared to the previous year[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 16.49% to RMB 24,482.88 million[5] - Basic earnings per share increased by 1.79% to RMB 1.14[4] - The weighted average return on net assets decreased by 0.19 percentage points to 12.05%[4] Assets and Equity - Total assets at the end of the reporting period were RMB 289,667.97 million, up 1.53% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 3.18% to RMB 233,742.56 million[5] Strategic Acquisitions - The company completed acquisitions of projects such as "Qinglu" in Nanjing and "Manxiangren" in Zhejiang, enhancing regional market layout[5] Investment Income - The company experienced a decrease in investment income of RMB 93.82 million due to market price fluctuations of indirectly held shares in Dongpeng Beverage[6] Operational Efficiency - The company continues to strengthen lean improvement, new product development, and supply chain management optimization to enhance operational efficiency[5]
卓越新能(688196) - 2025 Q4 - 年度业绩
2026-02-03 09:45
Financial Performance - Total revenue for 2025 was RMB 294,224.61 million, a decrease of 17.43% compared to RMB 356,332.52 million in the previous year[4] - Operating profit increased by 15.83% to RMB 17,847.86 million from RMB 15,408.38 million year-on-year[4] - Net profit attributable to shareholders of the parent company rose by 14.16% to RMB 17,011.54 million from RMB 14,901.88 million[4] - Net profit excluding non-recurring gains and losses increased significantly by 40.95% to RMB 19,008.08 million, driven by higher sales profits[6] - Basic earnings per share increased to RMB 1.40, up 12.90% from RMB 1.24 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 402,326.40 million, reflecting a growth of 12.81% from RMB 356,631.14 million at the beginning of the period[4] - Equity attributable to shareholders of the parent company increased by 14.40% to RMB 319,492.01 million from RMB 279,272.77 million[5] Return on Investment - The company’s weighted average return on net assets improved by 0.43 percentage points to 5.88%[4] Operational Insights - The increase in operating performance was attributed to strategic adjustments and improved product gross margins, along with the commissioning of the natural fatty alcohol production line[6] - There are no significant uncertainties affecting the accuracy of the performance report[7]
中原传媒(000719) - 2025 Q4 - 年度业绩
2026-02-03 09:25
证券代码:000719 证券简称:中原传媒 公告编号:2026-001 中原大地传媒股份有限公司 报告期公司经营稳健,实现营业总收入93.51亿元,同比下降 5.13%;实现营业利润14.50亿元,同比增长9.09%;利润总额14.50 亿元,同比增长9.48%;归属于上市公司股东的净利润13.49亿元,同 比增长30.99%;扣除非经常性损益后的归属于上市公司股东的净利润 13.22亿元,同比增长5.76%。基本每股收益1.32元,同比增长30.69%。 2025 年度业绩快报 本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记 载、没有误导性陈述或重大遗漏。 特别提示:本公告所载2025年度的财务数据仅为初步核算数据, 未经会计师事务所审计,与年度报告中披露的最终数据可能存在差 异,请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位:万元 | 项 目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 935,135.36 | 985,691.21 | -5.13 | | 营业利润 | 145,037.7 ...
雅葆轩(920357) - 2025 Q4 - 年度业绩
2026-02-03 09:20
证券代码:920357 证券简称:雅葆轩 公告编号:2026-002 芜湖雅葆轩电子科技股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示:本公告所载 2025 年年度主要财务数据为初步核算数据,未经会 计师事务所审计,具体数据以公司 2025 年年度报告中披露的数据为准,提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 | 单位:元 | | --- | | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 598,163,475.09 | 376,834,740.01 | 58.73% | | 利润总额 | 74,538,833.98 | 54,536,281.41 | 36.68% | | 归属于上市公司股东的净利 | 64,750,994.33 | 48,265,721.61 | 34.16% | | 润 | | | | | 归属于上市公司股东的扣除 | 6 ...
雷特科技(920110) - 2025 Q4 - 年度业绩
2026-02-03 09:10
证券代码:920110 证券简称:雷特科技 公告编号:2026-001 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 特别提示:本公告所载 2025 年年度主要财务数据为初步核算数据,未经会 计师事务所审计,具体数据以公司 2025 年年度报告中披露的数据为准,提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位:元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 201,342,016.11 | 200,088,021.77 | 0.63% | | 利润总额 | 50,217,936.09 | 49,435,152.91 | 1.58% | | 归属于上市公司股 | 45,864,327.99 | 44,780,952.11 | 2.42% | | 东的净利润 | | | | | 归属于上市公司股 东的扣除非经常性 | 43,952,633.21 | 41,241,995.96 | 6.57% | | 损益的净利润 | | | | | 基本每股收益 | 1.18 | 1.15 | 2.61% | ...
药康生物(688046) - 2025 Q4 - 年度业绩
2026-02-03 07:55
Financial Performance - The company achieved total operating revenue of RMB 79,325.46 million, an increase of 15.49% compared to the same period last year [2]. - Net profit attributable to shareholders of the parent company reached RMB 14,439.76 million, reflecting a growth of 31.49% year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 11,800.96 million, up 55.80% from the previous year [2]. - Basic earnings per share increased to RMB 0.35, representing a 29.63% rise compared to the same period last year [2]. Assets and Equity - Total assets at the end of the reporting period were RMB 287,275.94 million, an increase of 11.67% from the beginning of the period [2]. - Shareholders' equity attributable to the parent company grew to RMB 222,949.53 million, a 4.44% increase from the beginning of the period [2]. Strategic Focus - The company focused on internationalization and innovation, expanding its overseas market presence and enhancing its R&D investment [7]. - The increase in operating revenue was driven by improved sales networks in North America, Europe, and Asia-Pacific, along with a recovery in domestic industrial customer demand [7]. - The company emphasized cost control, resulting in a decrease in the expense ratio compared to the previous year [7]. Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and subject to audit, with final figures to be disclosed in the official annual report [8].
高铁电气(688285) - 2025 Q4 - 年度业绩
2026-02-03 07:55
Financial Performance - In 2025, the company achieved total operating revenue of RMB 118,110.55 million, an increase of 17.16% compared to the previous year[3] - The net profit attributable to shareholders of the parent company reached RMB 5,146.15 million, reflecting a growth of 14.02% year-on-year[6] - The operating profit increased by 39.58% year-on-year, driven by higher operating revenue and a focus on lean production and management[7] - The basic earnings per share for 2025 was RMB 0.1368, an increase of 14.10% compared to the previous year[6] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, was RMB 4,363.46 million, up 9.29% year-on-year[6] - The company's total operating profit and total profit both grew by 39.58% year-on-year, indicating strong operational performance[7] Assets and Equity - The total assets at the end of 2025 amounted to RMB 313,402.29 million, up 1.91% from the end of the previous year[7] - The equity attributable to shareholders of the parent company was RMB 169,007.50 million, representing a growth of 2.67% year-on-year[7] Return on Investment - The weighted average return on net assets increased by 0.31 percentage points to 3.08%[4] Audit and Investment Risks - The data presented is preliminary and subject to change upon final audit, with investors advised to consider investment risks[8]